Loading
A phase 2 trial of Etoposide, Carboplatin, Paclitaxel / nab-paclitaxel in small-cell lung cancer, run by BioNTech SE, active and no longer recruiting.
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy is a phase 2 interventional study registered as NCT06449209 by BioNTech SE, with 110 participants planned, started 2024-08-05 and due to reach its primary completion in 2027-06. Interventions recorded: BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2), Etoposide, Carboplatin, Paclitaxel. Conditions listed: Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares BioNTech, Extensive-stage small-cell lung cancer, Etoposide, Small-cell lung cancer.
Shares BioNTech, Extensive-stage small-cell lung cancer, Etoposide, Carboplatin.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares BioNTech, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Etoposide, Carboplatin, Small-cell lung cancer.